Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. EJE PRIZE 2018: A gut feeling about glucagon

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Roux-en-Y gastric bypass (RYGB) is one of the most common bariatric surgeries. The procedure induces a sustained weight loss together with a reduction in obesity-related comorbidities including type 2 diabetes. The effects on postprandial glucose metabolism are evident within days or weeks after surgery - before any weight loss has occurred - and are thought to be achieved by a faster passage of nutrients to the small intestine and ensuing alterations in the secretion of several gastrointestinal hormones, acceleration of glucose absorption and increased insulin secretion. Especially the remarkable increase in postprandial plasma levels of the gut-derived incretin hormone glucagon-like peptide 1 (GLP-1) - with not only a potent insulinotropic effect, but also a glucagonostatic effect - is believed to contribute to the metabolic improvements and the early remission of type 2 diabetes seen after RYGB.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind181
Udgave nummer3
Sider (fra-til)5-8
Antal sider4
ISSN0804-4643
DOI
StatusUdgivet - jul. 2019

ID: 58138553